Authoratory™
 
This website is accredited by Health On the Net Foundation. Click to verify.
Bookmark and Share

4Gary T Kinasewitz

 

Summary for 2002 [at-glance overview of Gary T Kinasewitz work for the selected year as suggested by data mining algorithms]

This is an Authoratory overview of author Gary T Kinasewitz. According to available data, in 2002 Gary T Kinasewitz published at least 4 articles. This work was completed in collaboration with several authors including Mulvihill, John J and Li, Shibo. Several other authors have collaborated with Gary T Kinasewitz as well. There is at least one grant awarded to support this work.

Analysis of the article abstracts and the titles suggests that Gary T Kinasewitz professional interests are focused around "drotrecogin alfa activated", "disseminated intravascular coagulation" and "exudative effusions congestive". These might also be referred to as "drotrecogin alfa", "alfa activated" or "intravascular coagulation". Statistical analysis shows that Gary T Kinasewitz's writing is likely to contains terms "patients", "hemostatic", "exudates", "activated", "factors" and "analysis".

Unfortunately, there is not enough information to establish Gary T Kinasewitz affiliation. Luckily, several email addresses are on file.

ENFRESRUAccurate information, makes sense to meInaccurate information, needs improvementmake correctionleave commentask question

Images [images we found on the Internet for Gary T Kinasewitz]

    loading...

    Do you know Gary T Kinasewitz who matches the profile above? Click the photo and let us know!

Alternative names (0) [other authors with names similar to Gary T Kinasewitz]

  • none

Year 2002 Charts [Gary T Kinasewitz frequent coauthors and the most common unique vocabulary terms for the selected year]

  • Gary T Kinasewitz - Coauthors & Social Network in 2002Gary T Kinasewitz - Unique Vocabulary, Keywords and Interests in 2002

Historical Performance Charts [graphical overview of Gary T Kinasewitz publication and funding history for the range of years]

  • Gary T Kinasewitz - Publications and Funding History in 2002

Emails (2) [email addresses extracted from Gary T Kinasewitz affiliations]

hidden to prevent spam, click here to reveal

Gary T Kinasewitz Coauthors (6) [all coauthors with the number of joint publications]

 

Other [context-specific ads]

Affiliations (4) [condensed summary of the Gary T Kinasewitz affiliations, the leading number and the color conveys importance]

  • 1Division of Pulmonary and Critical Care Medicine, University of Miami School of Medicine, Critical Care Medicine (III), 11300 Northeast Second Avenue, Miami Shore, FL 33125, USA.
    1Departments of Pulmonary and Critical Care Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
    1Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, OK 73104, USA.
    1Department of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.

Key Opinion Leader In [Gary T Kinasewitz is considered a key opinion leader in any keyword where the rank of 5 is achieved, the leading number before the keyword shows the author's rank as compared to all other authors]

  • no keywords assigned

Keywords (32) [keywords assigned to Gary T Kinasewitz articles by PubMed, the leading number and the color conveys importance]

  • 4Humans | 2Middle Aged | 2Female | 1Systemic Inflammatory Response Syndrome | 1Protein C | 1Patient Selection | 1Gene Duplication | 1Chromosomes, Human, Pair 15 | 1Recombinant Proteins | 1Hemorrhage | 1Hematologic Tests | 1Exudates and Transudates | 1Risk Factors | 1Adult | 1Disseminated Intravascular Coagulation | 1Blood Coagulation | 1Epidemiologic Factors | 1Anti-Inflammatory Agents, Non-Steroidal | 1Pleural Effusion | 1Biological Markers | 1Leukemia, Myelocytic, Acute | 1Disease Management | 1Anti-Infective Agents | 1Fibrinolytic Agents | 1Risk Assessment | 1Chromosomes, Human, Pair 8 | 1In Situ Hybridization, Fluorescence | 1Translocation, Genetic | 1Clinical Trials, Phase III as Topic | 1Blood Proteins | 1APACHE | 1Aged

Gary T Kinasewitz Unique Vocabulary (96) [single words, word pairs and phrases obtained by analysis of abstracts and titles, the leading number and the color conveys importance; Gary T Kinasewitz might be a good expert witness on these terms]

  • 11patients | 6hemostatic | 5exudates | 5activated | 4factors | 4analysis | 4exudative | 4sepsis | 4treatment | 4coagulation | 4drotrecogin | 4dic | 4effusions | 4alfa | 3chf | 3failure | 3diagnosis | 3disseminated | 3intravascular | 3risk-benefit | 3risk | 3response | 3acute | 3patient | 3review | 3pleural | 2benefits | 2organ | 2biomarkers | 2activation | 2severe | 2can
  • 4drotrecogin alfa | 4alfa activated | 3intravascular coagulation | 3exudative effusions | 3disseminated intravascular | 3hemostatic factors | 3risk-benefit analysis | 2severe sepsis | 2diagnosis management | 2effusions congestive | 2part review | 2analysis drotrecogin | 2heart failure | 2management disseminated | 2activation hemostatic | 2congestive heart | 2patient acute | 215q patient | 2nonovert dic | 2leukemia m2 | 2duplication 15q | 2myeloblastic leukemia | 2acute myeloblastic | 1persistent impairment | 1compound shown | 1inhibitor treatment | 1factors activated | 1overridden procoagulant | 1venules anticoagulant | 1hemostatic system | 1acute organ | 1careful risk-benefit
  • 4drotrecogin alfa activated | 3disseminated intravascular coagulation | 2exudative effusions congestive | 2management disseminated intravascular | 2effusions congestive heart | 2risk-benefit analysis drotrecogin | 2congestive heart failure | 2diagnosis management disseminated | 2analysis drotrecogin alfa | 2patient acute myeloblastic | 2myeloblastic leukemia m2 | 215q patient acute | 2duplication 15q patient | 2acute myeloblastic leukemia | 1reduce significantly risk | 1protein thrombomodulin tissue | 1endothelium protein thrombomodulin | 1anticoagulant anti-inflammatory regulatory | 1discuss bleeding potential | 1frequency exudates patients | 1activated conclusion patients | 1activity syndrome ranges | 1effusion hemostatic regulators | 1activation hemostatic system | 1circulating hemostatic factors | 1recipients year prior | 1risk death patients | 1diagnosing following response | 1persistent impairment lymphatic | 1m2 duplication 15q | 1criteria diagnosis nonovert | 1pleural cavity link

Reader's Comments (0) [comments posted by readers of Gary T Kinasewitz profile]

no comments yet

Funding (1) [selected NIH grants to Gary T Kinasewitz and the award amounts for recent years]

  • THE DYNAMICS OF VISCERAL PLEURAL FLUID EXCHANGE (KINASEWITZ, GARY - 1983)
    Grant #Award YearAward Amount, USD
    award information is not available
    Total up to 2002$NA

Gary T Kinasewitz Articles (4) [selected PubMed articles for the year 2002 with the links to a full text at PubMed]

  • Risk-benefit analysis for drotrecogin alfa (activated). (2002) >>

    Division of Pulmonary and Critical Care Medicine, University of Miami School of Medicine, Critical Care Medicine (III), 11300 Northeast Second Avenue, Miami Shore, FL 33125, USA.

    2Schein, Roland M H, 4Kinasewitz, Gary T.
  • Exudative effusions in congestive heart failure. (2002) >>

    Departments of Pulmonary and Critical Care Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.

    1Samaha, Michel, 1Keddissi, Jean I, 1Tawk, Maroun M, 4Kinasewitz, Gary T, 1Kimmell, Kristopher, 1Eid, Alain A.
  • The diagnosis and management of disseminated intravascular coagulation. (2002) >>

    Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, OK 73104, USA.

    3Taylor, Fletcher B, 4Kinasewitz, Gary T.
  • Duplication 15q in a patient with t(8;21) acute myeloblastic leukemia (M2). (2002) >>

    Department of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.

    1Bates, Francesca, 4Kinasewitz, Gary T, 5Zhang, Lijun, 1Scott, Kelley V, 7Mulvihill, John J, 5Li, Shibo.

Science Trivia (2) [Interactive math & science trivia questions]